Supercharged CAR t cells take on tough lymphoma
NCT ID NCT05989204
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing a new type of immune cell therapy called TmCD19-IL18 CAR T cells in people with a blood cancer (non-Hodgkin lymphoma) that has come back or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them to better recognize and attack cancer cells, and giving them back. The main goals are to find the safest dose and see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TmCD19-IL18 CAR T cells (a type of immune cell therapy that targets CD19 and releases IL-18 to boost the immune response)
What this could lead to
If successful, this could lead to a more effective treatment for certain blood cancers that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 24 participants, so it is too soon to know if it will work. There are risks of serious side effects, including cytokine release syndrome and neurological issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••